Thread

👉 Kimberly-Clark's $50 billion offer for Kenvue is a significant move into new categories like skin care and pain relief. 👉 Analysts are skeptical about the deal's strategic fit and potential cost savings. 👉 The combined company will face regulatory challenges in the over-the-counter drug category. 👉 Kimberly-Clark may struggle to grow in a market where lower-income shoppers are trimming their budgets.